Shares of National Research Co. (NASDAQ:NRCIB) have earned a consensus broker rating score of 3.00 (Hold) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation.

Brokerages have set a 1 year consensus price target of $44.00 for the company and are anticipating that the company will post $0.27 EPS for the current quarter, according to Zacks. Zacks has also assigned National Research an industry rank of 115 out of 265 based on the ratings given to related companies.

National Research (NASDAQ NRCIB) traded down $1.35 during trading hours on Thursday, reaching $52.13. The company’s stock had a trading volume of 5,600 shares, compared to its average volume of 3,067. The company has a market capitalization of $1,309.30, a price-to-earnings ratio of 75.32 and a beta of 0.07. National Research has a 12-month low of $38.50 and a 12-month high of $57.21.

Several institutional investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. acquired a new position in shares of National Research in the third quarter valued at approximately $215,000. Tudor Investment Corp ET AL acquired a new stake in National Research during the second quarter worth approximately $243,000. Willis Investment Counsel grew its position in National Research by 1.7% during the second quarter. Willis Investment Counsel now owns 29,042 shares of the business services provider’s stock worth $1,379,000 after buying an additional 490 shares in the last quarter. California Public Employees Retirement System acquired a new stake in National Research during the second quarter worth approximately $224,000. Finally, WCM Investment Management CA grew its position in National Research by 1.1% during the second quarter. WCM Investment Management CA now owns 51,423 shares of the business services provider’s stock worth $2,455,000 after buying an additional 560 shares in the last quarter. 2.61% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Set $44.00 Target Price for National Research Co. (NRCIB)” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/07/zacks-brokerages-set-44-00-target-price-for-national-research-co-nrcib.html.

National Research Company Profile

National Research Corporation provides analytics and insights for the patient and employee experience in serving the healthcare providers, payers, and other healthcare organizations in the United States and Canada. Its portfolio of subscription-based solutions offer information and analysis services in a range of elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.

Get a free copy of the Zacks research report on National Research (NRCIB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for National Research Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research Co. and related companies with MarketBeat.com's FREE daily email newsletter.